Home » Stocks » IGM Biosciences

IGM Biosciences, Inc. (IGMS)

Stock Price: $60.92 USD 1.87 (3.17%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 1.87B
Revenue (ttm) n/a
Net Income (ttm) -61.45M
Shares Out 24.22M
EPS (ttm) -26.20
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 23, 2020
Last Price $60.92
Previous Close $59.05
Change ($) 1.87
Change (%) 3.17%
Day's Open 59.16
Day's Range 58.53 - 63.06
Day's Volume 190,148
52-Week Range 19.43 - 89.81

More Stats

Market Cap 1.87B
Enterprise Value 1.68B
Earnings Date (est) Nov 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 24.22M
Float 13.09M
EPS (basic) 7.72
EPS (diluted) -26.20
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.57M
Short Ratio 6.97
Short % of Float 11.97%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 11.75
Revenue n/a
Operating Income -64.59M
Net Income -61.45M
Free Cash Flow n/a
Net Cash 184.58M
Net Cash / Share 6.02
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -29.09%
ROE -49.40%
ROIC -34.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (9)

Buy 8
Overweight 1
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(35.14% upside)
Current: $60.92
Target: 82.33
*Average 12-month price target from 9 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-44.50-22.79-11.15
Net Income-43.13-22.71-11.05
Shares Outstanding9.000.440.44
Earnings Per Share-4.80-51.84-25.24
Operating Cash Flow-45.12-20.04-10.36
Capital Expenditures-2.34-0.79-0.39
Free Cash Flow-47.45-20.83-10.74
Cash & Equivalents2251.990.48
Total Debt14.735.03-
Net Cash / Debt210-3.040.48
Book Value240-65.83-40.50
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name IGM Biosciences, Inc.
Country United States
Employees 91
CEO Fred M. Schwarzer

Stock Information

Ticker Symbol IGMS
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: IGMS
IPO Date September 18, 2019


IGM Biosciences, a biotechnology company, engages in the research and development of Immunoglobulin M (IgM) antibodies for the treatment of cancer. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 1 clinical trials to treat patients with B cell NHL and other B cell malignancies. It is also developing IGM-8444, an IgM antibody targeting Death Receptor 5 proteins; and IGM-7354, is a bispecific IgM antibody delivering interleukin-15 cytokines to PD-L1 expressing cells for use in the treatment of patients with solid and hematologic malignancies. IGM Biosciences, Inc. has a collaboration with Atreca Inc. and BeiGene Ltd. to discover, develop, and manufacture novel IgM and IgA antibodies targeting SARS-CoV-2 for the potential treatment of COVID-19; and strategic research collaboration and license agreement with AbCellera to discover and develop IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.